Pramipexole Teva

Țară: Uniunea Europeană

Limbă: engleză

Sursă: EMA (European Medicines Agency)

Cumpara asta acum

Prospect Prospect (PIL)
23-11-2021

Ingredient activ:

pramipexole dihydrochloride monohydrate

Disponibil de la:

Teva Pharma B.V.

Codul ATC:

N04BC05

INN (nume internaţional):

pramipexole

Grupul Terapeutică:

Anti-Parkinson drugs

Zonă Terapeutică:

Parkinson Disease

Indicații terapeutice:

Pramipexole Teva is indicated for treatment of the signs and symptoms of idiopathic Parkinson's disease, alone (without levodopa) or in combination with levodopa, i.e. over the course of the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end-of-dose or 'on-off' fluctuations).Pramipexole Teva is indicated in adults for symptomatic treatment of moderate to severe idiopathic Restless Legs Syndrome in doses up to 0.54 mg of base (0.75 mg of salt) (see section 4.2).

Rezumat produs:

Revision: 22

Statutul autorizaţiei:

Authorised

Data de autorizare:

2008-12-18

Prospect

                                43
B. PACKAGE LEAFLET
44
PACKAGE LEAFLET: INFORMATION FOR THE USER
PRAMIPEXOLE TEVA 0.088 MG TABLETS
PRAMIPEXOLE TEVA 0.18 MG TABLETS
PRAMIPEXOLE TEVA 0.35 MG TABLETS
PRAMIPEXOLE TEVA 0.7 MG TABLETS
pramipexole
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
•
Keep this leaflet. You may need to read it again.
•
If you have any further questions, ask your doctor or pharmacist.
•
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
•
If you get any of the side effects, talk to your doctor or pharmacist.
This includes any possible
side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Pramipexole Teva is and what it is used for
2.
What you need to know before you take Pramipexole Teva
3.
How to take Pramipexole Teva
4.
Possible side effects
5.
How to store Pramipexole Teva
6.
Contents of the pack and other information
1.
WHAT PRAMIPEXOLE TEVA IS AND WHAT IT IS USED FOR
Pramipexole Teva contains the active substance pramipexole and belongs
to a group of medicines
known as dopamine agonists,
_ _
which stimulate dopamine receptors in the brain. Stimulation of the
dopamine receptors triggers nerve impulses in the brain that help to
control body movements.
Pramipexole Teva is used to:
•
treat the symptoms of primary Parkinson’s disease in adults. It can
be used alone or in
combination with levodopa (another medicine for Parkinson’s
disease).
•
treat the symptoms of moderate to severe primary Restless Legs
Syndrome in adults.
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE PRAMIPEXOLE TEVA
DO NOT TAKE PRAMIPEXOLE TEVA
•
if you are allergic to pramipexole or to any of the other ingredients
of this medicine (listed in
section 6).
WARNINGS AND PRECAUTIONS
Talk to your doctor before taking Pramipexole Teva. Tell your doctor
if you have (had) or develop any
medical conditions or symptoms, especially any of the foll
                                
                                Citiți documentul complet
                                
                            

Caracteristicilor produsului

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1. NAME OF THE MEDICINAL PRODUCT
Pramipexole Teva 0.088 mg tablets
Pramipexole Teva 0.18 mg tablets
Pramipexole Teva 0.35 mg tablets
Pramipexole Teva 0.7 mg tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Pramipexole Teva 0.088 mg tablets
Each tablet contains 0.125 mg pramipexole dihydrochloride monohydrate
equivalent to 0.088 mg
pramipexole.
Pramipexole Teva 0.18 mg tablets
Each tablet contains 0.25 mg pramipexole dihydrochloride monohydrate
equivalent to 0.18 mg
pramipexole.
Pramipexole Teva 0.35 mg tablets
Each tablet contains 0.5 mg pramipexole dihydrochloride monohydrate
equivalent to 0.35 mg
pramipexole.
Pramipexole Teva 0.7 mg tablets
Each tablet contains 1.0 mg pramipexole dihydrochloride monohydrate
equivalent to 0.7 mg
pramipexole.
_Please note: _
Pramipexole doses as published in the literature refer to the salt
form.
Therefore, doses will be expressed in terms of both pramipexole base
and pramipexole salt (in
brackets).
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Tablet
Pramipexole Teva 0.088 mg tablets
White, round, flat face bevel edge tablet, 5.55 mm diameter, embossed
with “93” on one side and “P1”
on the other side.
Pramipexole Teva 0.18 mg tablets
White, round, flat face bevel edge tablet, 7.00 mm diameter, embossed
with "P2" over "P2" on the
scored side and "93" on the other side. The tablet can be divided into
equal halves.
Pramipexole Teva 0.35 mg tablets
White to off-white, oval, biconvex tablets, engraved with 9 vertical
scoreline 3 on the scored side, and
8023 on the other side. The tablet can be divided into equal halves.
Pramipexole Teva 0.7 mg tablets
White, round, flat face bevel edge tablet, 8.82 mm diameter, embossed
with "8024" over "8024" on the
scored side and "93" on the other side. The tablet can be divided into
equal halves.
3
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Pramipexole Teva is indicated in adults for treatment of the signs and
symptoms of idiopathic
Parkinson’s disease
                                
                                Citiți documentul complet
                                
                            

Documente în alte limbi

Prospect Prospect bulgară 23-11-2021
Caracteristicilor produsului Caracteristicilor produsului bulgară 23-11-2021
Raport public de evaluare Raport public de evaluare bulgară 21-07-2013
Prospect Prospect spaniolă 23-11-2021
Caracteristicilor produsului Caracteristicilor produsului spaniolă 23-11-2021
Raport public de evaluare Raport public de evaluare spaniolă 21-07-2013
Prospect Prospect cehă 23-11-2021
Caracteristicilor produsului Caracteristicilor produsului cehă 23-11-2021
Raport public de evaluare Raport public de evaluare cehă 21-07-2013
Prospect Prospect daneză 23-11-2021
Caracteristicilor produsului Caracteristicilor produsului daneză 23-11-2021
Raport public de evaluare Raport public de evaluare daneză 21-07-2013
Prospect Prospect germană 23-11-2021
Caracteristicilor produsului Caracteristicilor produsului germană 23-11-2021
Raport public de evaluare Raport public de evaluare germană 21-07-2013
Prospect Prospect estoniană 23-11-2021
Caracteristicilor produsului Caracteristicilor produsului estoniană 23-11-2021
Raport public de evaluare Raport public de evaluare estoniană 21-07-2013
Prospect Prospect greacă 23-11-2021
Caracteristicilor produsului Caracteristicilor produsului greacă 23-11-2021
Raport public de evaluare Raport public de evaluare greacă 21-07-2013
Prospect Prospect franceză 23-11-2021
Caracteristicilor produsului Caracteristicilor produsului franceză 23-11-2021
Raport public de evaluare Raport public de evaluare franceză 21-07-2013
Prospect Prospect italiană 23-11-2021
Caracteristicilor produsului Caracteristicilor produsului italiană 23-11-2021
Raport public de evaluare Raport public de evaluare italiană 21-07-2013
Prospect Prospect letonă 23-11-2021
Caracteristicilor produsului Caracteristicilor produsului letonă 23-11-2021
Raport public de evaluare Raport public de evaluare letonă 21-07-2013
Prospect Prospect lituaniană 23-11-2021
Caracteristicilor produsului Caracteristicilor produsului lituaniană 23-11-2021
Raport public de evaluare Raport public de evaluare lituaniană 21-07-2013
Prospect Prospect maghiară 23-11-2021
Caracteristicilor produsului Caracteristicilor produsului maghiară 23-11-2021
Raport public de evaluare Raport public de evaluare maghiară 21-07-2013
Prospect Prospect malteză 23-11-2021
Caracteristicilor produsului Caracteristicilor produsului malteză 23-11-2021
Raport public de evaluare Raport public de evaluare malteză 21-07-2013
Prospect Prospect olandeză 23-11-2021
Caracteristicilor produsului Caracteristicilor produsului olandeză 23-11-2021
Raport public de evaluare Raport public de evaluare olandeză 21-07-2013
Prospect Prospect poloneză 23-11-2021
Caracteristicilor produsului Caracteristicilor produsului poloneză 23-11-2021
Raport public de evaluare Raport public de evaluare poloneză 21-07-2013
Prospect Prospect portugheză 23-11-2021
Caracteristicilor produsului Caracteristicilor produsului portugheză 23-11-2021
Raport public de evaluare Raport public de evaluare portugheză 21-07-2013
Prospect Prospect română 23-11-2021
Caracteristicilor produsului Caracteristicilor produsului română 23-11-2021
Raport public de evaluare Raport public de evaluare română 21-07-2013
Prospect Prospect slovacă 23-11-2021
Caracteristicilor produsului Caracteristicilor produsului slovacă 23-11-2021
Raport public de evaluare Raport public de evaluare slovacă 21-07-2013
Prospect Prospect slovenă 23-11-2021
Caracteristicilor produsului Caracteristicilor produsului slovenă 23-11-2021
Raport public de evaluare Raport public de evaluare slovenă 21-07-2013
Prospect Prospect finlandeză 23-11-2021
Caracteristicilor produsului Caracteristicilor produsului finlandeză 23-11-2021
Raport public de evaluare Raport public de evaluare finlandeză 21-07-2013
Prospect Prospect suedeză 23-11-2021
Caracteristicilor produsului Caracteristicilor produsului suedeză 23-11-2021
Raport public de evaluare Raport public de evaluare suedeză 21-07-2013
Prospect Prospect norvegiană 23-11-2021
Caracteristicilor produsului Caracteristicilor produsului norvegiană 23-11-2021
Prospect Prospect islandeză 23-11-2021
Caracteristicilor produsului Caracteristicilor produsului islandeză 23-11-2021
Prospect Prospect croată 23-11-2021
Caracteristicilor produsului Caracteristicilor produsului croată 23-11-2021

Căutați alerte legate de acest produs

Vizualizați istoricul documentelor